Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.58 |
| ▸ | AGXT | P21549 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 5/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2357432 | 0.79 | IDO1 (0.58) | IDO1AGXTMAOBAPPKMT2A | |
| SCHEMBL4995796 | 0.78 | IDO1 (0.64) | IDO1AGXTMAOBAPPKMT2A | |
| SCHEMBL357428 | 0.78 | IDO1 (0.64) | IDO1AGXTMAOBAPPKMT2A | |
| SCHEMBL8995755 | 0.76 | IDO1 (0.61) | IDO1AGXTMAOBAPPKMT2A | |
| SCHEMBL9821418 | 0.76 | IDO1 (0.61) | IDO1AGXTMAOBAPPKMT2A | |
| SCHEMBL9068656 | 0.76 | IDO1 (0.56) | IDO1APPKMT2ATAAR1LMNA | |
| SCHEMBL1109924 | 0.75 | IDO1 (0.54) | IDO1AGXTMAOBAPPKMT2A | |
| SCHEMBL1139040 | 0.74 | IDO1 (0.58) | IDO1AGXTMAOBAPPKMT2A | |
| SCHEMBL2095571 | 0.74 | IDO1 (0.58) | IDO1AGXTKMT2ALMNAMEN1 | |
| SCHEMBL4800547 | 0.74 | IDO1 (0.58) | IDO1MAOBAPPKMT2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6274715-B1 | SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY | ABBOTT LABORATORIES | 2001-08-14 | — | — | US | claimed |
| EP-0961776-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | claimed |
| US-4338437-A | Cephalosporin antibiotics | MERCK & CO., INC. (US) | 1982-07-06 | — | — | US | claimed |
| US-4181733-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1980-01-01 | — | — | US | claimed |
| JP-59025348-A | — | — | None | — | — | JP | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| CN-112154167-A | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2020-12-29 | — | — | CN | disclosed |
| US-4150145-A | ANTIBIOTIC, BACTERICIDES | MERCK & CO., INC. (US) | 1979-04-17 | — | — | US | disclosed |
| US-4150156-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1979-04-17 | — | — | US | disclosed |
| EP-0001264-A1 | Substituted N-methylene derivatives of thienamycin sulfoxide and sulfone and their preparation | MERCK & CO. INC. (US) | 1979-04-04 | — | — | EP | disclosed |
| EP-0001265-A1 | O-, N- and carboxyl derivatives of thienamycin sulfoxide and sulfone, their preparation and pharmaceuticals containing said compounds | MERCK & CO. INC. (US) | 1979-04-04 | — | — | EP | disclosed |
| US-4123528-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1978-10-31 | — | — | US | disclosed |
| US-4078067-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4078068-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4076826-A | ANTIBIOTIC | MERCK & CO., INC. (US) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | IDO1 4109/4885AGXT 2996/4885MAOB 4852/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | IDO1 4638/4885AGXT 3821/4885MAOB 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.